HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Zinc gluconate lozenges for treating the common cold. A randomized, double-blind, placebo-controlled study.

AbstractBACKGROUND:
The common cold is one of the most frequent human illnesses and is responsible for substantial morbidity and economic loss. No consistently effective therapy for the common cold has been well documented, but evidence suggests that several possible mechanisms may make zinc an effective treatment.
OBJECTIVE:
To test the efficacy of zinc gluconate lozenges in reducing the duration of symptoms caused by the common cold.
DESIGN:
Randomized, double-blind, placebo-controlled study.
SETTING:
Outpatient department of a large tertiary care center.
PATIENTS:
100 employees of the Cleveland Clinic who developed symptoms of the common cold within 24 hours before enrollment.
INTERVENTION:
Patients in the zinc group (n = 50) received lozenges (one lozenge every 2 hours while awake) containing 13.3 mg of zinc from zinc gluconate as long as they had cold symptoms. Patients in the placebo group (n = 50) received similarly administered lozenges that contained 5% calcium lactate pentahydrate instead of zinc gluconate.
MAIN OUTCOME MEASURES:
Subjective daily symptom scores for cough, headache, hoarseness, muscle ache, nasal drainage, nasal congestion, scratchy throat, sore throat, sneezing, and fever (assessed by oral temperature).
RESULTS:
The time to complete resolution of symptoms was significantly shorter in the zinc group than in the placebo group (median, 4.4 days compared with 7.6 days; P < 0.001). The zinc group had significantly fewer days with coughing (median, 2.0 days compared with 4.5 days; P = 0.04), headache (2.0 days and 3.0 days; P = 0.02), hoarseness (2.0 days and 3.0 days; P = 0.02), nasal congestion (4.0 days and 6.0 days; P = 0.002), nasal drainage (4.0 days and 7.0 days; P < 0.001), and sore throat (1.0 day and 3.0 days; P < 0.001). The groups did not differ significantly in the resolution of fever, muscle ache, scratchy throat, or sneezing. More patients in the zinc group than in the placebo group had side effects (90% compared with 62%; P < 0.001), nausea (20% compared with 4%; P = 0.02), and bad-taste reactions (80% compared with 30%; P < 0.001),
CONCLUSION:
Zinc gluconate in the form and dosage studied significantly reduced the duration of symptoms of the common cold. The mechanism of action of this substance in treating the common cold remains unknown. Individual patients must decide whether the possible beneficial effects of zinc gluconate on cold symptoms outweigh the possible adverse effects.
AuthorsS B Mossad, M L Macknin, S V Medendorp, P Mason
JournalAnnals of internal medicine (Ann Intern Med) Vol. 125 Issue 2 Pg. 81-8 (Jul 15 1996) ISSN: 0003-4819 [Print] United States
PMID8678384 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Gluconates
  • Zinc
  • gluconic acid
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Common Cold (drug therapy)
  • Cough (drug therapy)
  • Double-Blind Method
  • Female
  • Fever (drug therapy)
  • Gluconates (administration & dosage, adverse effects, therapeutic use)
  • Headache (drug therapy)
  • Hoarseness (drug therapy)
  • Humans
  • Male
  • Middle Aged
  • Muscles
  • Pain (drug therapy)
  • Pharyngitis (drug therapy)
  • Rhinitis (drug therapy)
  • Sneezing
  • Time Factors
  • Treatment Outcome
  • Zinc (administration & dosage, adverse effects, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: